Sagimet Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Sagimet Biosciences Inc. (SGMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 147 shares for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2025-11-13
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 147.00 shares, a 99.94% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-12-31 was 112.28K shares, a 449040.00% increase year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 900.73K shares, a 172122.94% increase from fiscal 2023.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 523.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-13 | 147.00 shares 10-Q · filed 2025-11-13 | 112.43K shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 147.00 shares 10-Q · filed 2025-08-13 | 112.43K shares derived: sum of 3 quarters · filed 2025-08-13 | 481.92K shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 147.00 shares 10-Q · filed 2025-05-08 | 112.43K shares derived: sum of 2 quarters · filed 2025-05-08 | 481.92K shares derived: sum of 3 quarters · filed 2025-05-08 | 645.68K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 112.28K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | 481.77K shares derived: sum of 2 quarters · filed 2025-03-12 | 645.54K shares derived: sum of 3 quarters · filed 2025-03-12 | 900.73K shares 10-K · filed 2025-03-12 |
| 2024-09-30 | 369.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 533.25K shares derived: sum of 2 quarters · filed 2024-11-14 | 788.44K shares 10-Q · filed 2024-11-14 | 788.47K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 163.76K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 418.95K shares 10-Q · filed 2024-08-14 | 418.98K shares derived: sum of 3 quarters · filed 2024-08-14 | |
| 2024-03-31 | 255.19K shares 10-Q · filed 2024-05-15 | 255.22K shares derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2023-12-31 | 25.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 523.00 shares 10-K · filed 2024-03-25 | ||
| 2023-09-30 | 498.00 shares 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |